CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Vivos Therapeutics, Inc. - VVOS CFD

19.69
18.54%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.27
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 24.17
Open* 19.16
1-Year Change* 3891.67%
Day's Range* 19.16 - 22.17
52 wk Range 0.18-2.96
Average Volume (10 days) 29.17M
Average Volume (3 months) 128.21M
Market Cap 9.23M
P/E Ratio -100.00K
Shares Outstanding 29.93M
Revenue 15.45M
EPS -0.77
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Dec 18, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 19.69 -0.57 -2.81% 20.26 22.95 18.92
Nov 30, 2023 24.17 -0.87 -3.47% 25.04 31.39 21.82
Nov 29, 2023 40.96 29.28 250.68% 11.68 48.48 9.82
Nov 28, 2023 4.37 0.24 5.81% 4.13 4.37 4.13
Nov 27, 2023 4.04 -0.31 -7.13% 4.35 4.35 4.02
Nov 24, 2023 4.24 0.28 7.07% 3.96 4.33 3.96
Nov 22, 2023 3.94 -0.72 -15.45% 4.66 4.66 3.94
Nov 21, 2023 4.47 0.18 4.20% 4.29 4.82 4.25
Nov 20, 2023 4.25 0.41 10.68% 3.84 4.43 3.83
Nov 17, 2023 3.94 0.11 2.87% 3.83 4.07 3.78
Nov 16, 2023 3.86 -0.08 -2.03% 3.94 3.99 3.74
Nov 15, 2023 3.83 0.04 1.06% 3.79 4.23 3.79
Nov 14, 2023 3.54 0.14 4.12% 3.40 3.70 3.35
Nov 13, 2023 3.27 0.56 20.66% 2.71 3.30 2.61
Nov 10, 2023 2.71 -0.07 -2.52% 2.78 2.78 2.70
Nov 9, 2023 2.88 -0.15 -4.95% 3.03 3.12 2.87
Nov 8, 2023 3.26 -0.17 -4.96% 3.43 3.43 2.98
Nov 7, 2023 3.38 -0.05 -1.46% 3.43 3.56 3.34
Nov 6, 2023 3.52 0.12 3.53% 3.40 3.68 3.26
Nov 3, 2023 3.40 -0.23 -6.34% 3.63 3.65 3.35

Vivos Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, December 18, 2023

Time (UTC)

10:59

Country

US

Event

Q2 2023 Vivos Therapeutics Inc Earnings Release
Q2 2023 Vivos Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 16.024 16.885 13.0662 11.3933 3.79226
Revenue 16.024 16.885 13.0662 11.3933 3.79226
Cost of Revenue, Total 6.005 4.281 2.65343 2.73603 1.08164
Gross Profit 10.019 12.604 10.4128 8.65725 2.71062
Total Operating Expense 39.768 37.267 25.1061 22.0308 12.1284
Selling/General/Admin. Expenses, Total 34.381 31.342 18.4041 18.4832 10.4361
Depreciation / Amortization 0.669 0.733 0.71787 0.75123 0.61067
Operating Income -23.744 -20.382 -12.0398 -10.6376 -8.33618
Interest Income (Expense), Net Non-Operating 0 0.103 -0.01707 -0.11675 -0.10297
Net Income Before Taxes -23.845 -20.288 -12.0569 -10.7543 -8.43916
Net Income After Taxes -23.845 -20.288 -12.0569 -10.7543 -8.43916
Net Income Before Extra. Items -23.845 -20.288 -12.0569 -10.7543 -8.43916
Net Income -23.845 -20.288 -12.0569 -10.7543 -8.43916
Income Available to Common Excl. Extra. Items -23.845 -20.288 -12.0569 -10.7543 -8.43916
Income Available to Common Incl. Extra. Items -23.845 -20.288 -12.0569 -10.7543 -8.43916
Diluted Net Income -23.845 -20.288 -12.0569 -10.7543 -8.43916
Diluted Weighted Average Shares 23.0121 21.233 18.2121 17.5 17.5
Diluted EPS Excluding Extraordinary Items -1.03619 -0.95549 -0.66202 -0.61453 -0.48224
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.09212 -0.91259 -0.66202 -0.61108 -0.48224
Unusual Expense (Income) -1.287 0.911 0 0.06034
Other Operating Expenses, Total 0 3.33068
Other, Net -0.101 -0.009
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3.395 3.857 3.95 4.246 4.184
Revenue 3.395 3.857 3.95 4.246 4.184
Cost of Revenue, Total 1.297 1.52 1.566 1.75 1.596
Gross Profit 2.098 2.337 2.384 2.496 2.588
Total Operating Expense 7.912 8.862 10.013 9.653 11.148
Selling/General/Admin. Expenses, Total 6.467 7.167 8.278 7.728 9.39
Depreciation / Amortization 0.148 0.175 0.169 0.175 0.162
Operating Income -4.517 -5.005 -6.063 -5.407 -6.964
Interest Income (Expense), Net Non-Operating 0
Net Income Before Taxes -5.528 -1.703 -6.089 -5.434 -6.992
Net Income After Taxes -5.528 -1.703 -6.089 -5.434 -6.992
Net Income Before Extra. Items -5.528 -1.703 -6.089 -5.434 -6.992
Net Income -5.528 -1.703 -6.089 -5.434 -6.992
Income Available to Common Excl. Extra. Items -5.528 -1.703 -6.089 -5.434 -6.992
Income Available to Common Incl. Extra. Items -5.528 -1.703 -6.089 -5.434 -6.992
Diluted Net Income -5.528 -1.703 -6.089 -5.434 -6.992
Diluted Weighted Average Shares 29.9288 24.764 23.0121 21.2335 21.2335
Diluted EPS Excluding Extraordinary Items -0.18471 -0.06877 -0.2646 -0.25592 -0.32929
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.18471 -0.06877 -0.2646 -0.25592 -0.32929
Unusual Expense (Income) 0 0 0 0 0
Other Operating Expenses, Total
Other, Net -1.011 3.302 -0.026 -0.027 -0.028
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 5.424 27.324 20.3943 1.98416 2.0116
Cash and Short Term Investments 3.519 24.03 18.2057 0.46935 1.25472
Cash & Equivalents 3.519 24.03 18.2057 0.46935 1.25472
Total Receivables, Net 0.457 1.203 1.51559 0.95599 0.59519
Accounts Receivable - Trade, Net 0.457 1.203 1.51559 0.95599 0.59519
Prepaid Expenses 1.448 1.575 0.67306 0.295 0.02776
Other Current Assets, Total 0 0.516 0 0.26381 0.13393
Total Assets 13.72 33.689 25.3275 7.55154 8.20397
Property/Plant/Equipment, Total - Net 4.777 2.825 0.8716 1.1395 1.28167
Property/Plant/Equipment, Total - Gross 6.53 4.068 1.67293 1.642 1.50952
Accumulated Depreciation, Total -1.753 -1.243 -0.80134 -0.5025 -0.22785
Goodwill, Net 2.843 2.843 2.67143 2.67143 3.74352
Intangibles, Net 0.302 0.341 0.27012 0.68915 1.14028
Note Receivable - Long Term 0 0.81064 0.78506 0
Other Long Term Assets, Total 0.374 0.356 0.30937 0.28224 0.02691
Total Current Liabilities 6.813 7.509 7.82305 9.09368 2.15716
Accounts Payable 1.411 0.92 2.28136 1.08342 0.47408
Accrued Expenses 2.331 2.853 1.73672 1.35316 0.63202
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 1.334 0.86697 3.70954 0.16155
Other Current Liabilities, Total 3.071 2.402 2.93799 2.94757 0.88951
Total Liabilities 8.919 8.15 8.41011 9.17793 2.71051
Total Long Term Debt 0 0.298 0.4231 0 0.525
Long Term Debt 0 0.4231 0 0.525
Other Liabilities, Total 2.106 0.343 0.16397 0.08425 0.02835
Total Equity 4.801 25.539 16.9174 -1.62639 5.49346
Redeemable Preferred Stock 0 0 0 1.31667 0.66667
Common Stock 0.002 0.002 0.00182 0.00124 0.00121
Additional Paid-In Capital 84.267 81.16 52.2503 20.3335 17.3491
Retained Earnings (Accumulated Deficit) -79.468 -55.623 -35.3347 -23.2778 -12.5235
Total Liabilities & Shareholders’ Equity 13.72 33.689 25.3275 7.55154 8.20397
Total Common Shares Outstanding 23.0121 23.0121 18.2121 17.6667 17.6667
Capital Lease Obligations 0 0.298
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 5.342 8.713 5.424 9.701 15.513
Cash and Short Term Investments 3.942 7.046 3.519 6.719 12.661
Cash & Equivalents 3.942 7.046 3.519 6.719 12.661
Total Receivables, Net 0.327 0.321 0.457 0.866 0.791
Accounts Receivable - Trade, Net 0.327 0.321 0.457 0.866 0.791
Prepaid Expenses 1.073 1.346 1.448 2.116 2.061
Total Assets 13.749 17.1 13.72 18.4 24.375
Property/Plant/Equipment, Total - Net 4.811 4.778 4.777 5.172 5.324
Property/Plant/Equipment, Total - Gross 6.864 6.695 6.53 6.765 6.751
Accumulated Depreciation, Total -2.053 -1.917 -1.753 -1.593 -1.427
Goodwill, Net 2.843 2.843 2.843 2.843 2.843
Intangibles, Net 0.445 0.458 0.302 0.312 0.322
Note Receivable - Long Term
Other Long Term Assets, Total 0.308 0.308 0.374 0.372 0.373
Total Current Liabilities 8.44 7.975 6.813 5.964 6.694
Accounts Payable 1.325 1.495 1.411 0.644 1.252
Accrued Expenses 2.396 2.373 2.331 2.625 3.001
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0
Other Current Liabilities, Total 4.719 4.107 3.071 2.695 2.441
Total Liabilities 11.643 10.107 8.919 8.545 9.536
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 3.203 2.132 2.106 2.581 2.842
Total Equity 2.106 6.993 4.801 9.855 14.839
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.003 0.003 0.002 0.002 0.002
Additional Paid-In Capital 88.802 88.161 84.267 83.233 82.783
Retained Earnings (Accumulated Deficit) -86.699 -81.171 -79.468 -73.38 -67.946
Total Liabilities & Shareholders’ Equity 13.749 17.1 13.72 18.4 24.375
Total Common Shares Outstanding 29.9288 29.9288 23.0121 23.0121 23.0121
Other Current Assets, Total 0 0 0
Capital Lease Obligations 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -23.845 -20.288 -12.0569 -10.7543 -8.43916
Cash From Operating Activities -19.587 -15.735 -5.68029 -5.34048 -5.31389
Cash From Operating Activities 0.669 0.733 0.71787 0.75123 0.61067
Non-Cash Items 1.878 3.792 6.08979 2.13069 1.64749
Changes in Working Capital 1.711 0.028 -0.43108 2.53193 0.8671
Cash From Investing Activities -0.924 -2.608 -0.12025 0.08622 -1.11725
Capital Expenditures -0.924 -2.396 -0.12025 -0.1756 -1.25059
Other Investing Cash Flow Items, Total 0 -0.212 0 0.26182 0.13334
Cash From Financing Activities 0 24.167 23.5369 4.46889 5.25303
Financing Cash Flow Items 0 -2.238 -0.24521 -0.15989 -0.10393
Issuance (Retirement) of Stock, Net 0 26.43 22.592 0.8985 5.4452
Issuance (Retirement) of Debt, Net 0 -0.025 1.19007 3.73028 -0.08824
Net Change in Cash -20.511 5.824 17.7363 -0.78537 -1.17811
Cash Taxes Paid 0 0
Cash Interest Paid 0.002 0.018 0.03317
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -1.703 -23.845 -17.756 -12.322 -5.331
Cash From Operating Activities -3.539 -19.587 -16.587 -10.745 -6.082
Cash From Operating Activities 0.175 0.669 0.5 0.324 0.041
Non-Cash Items -2.244 1.878 1.227 0.633 -0.434
Cash Taxes Paid 0
Cash Interest Paid 0 0.002 0.002 0.002 0.002
Changes in Working Capital 0.233 1.711 -0.558 0.62 -0.358
Cash From Investing Activities -0.289 -0.924 -0.724 -0.624 -0.12
Capital Expenditures -0.239 -0.924 -0.724 -0.624 -0.12
Cash From Financing Activities 7.355 0 0 0 0
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash 3.527 -20.511 -17.311 -11.369 -6.202
Other Investing Cash Flow Items, Total -0.05 0 0 0
Financing Cash Flow Items -0.645 0
Issuance (Retirement) of Stock, Net 8 0 0 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vivos Therapeutics, Inc. Company profile

About Vivos Therapeutics Inc

Vivos Therapeutics, Inc. is a medical technology company. The Company is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The Company's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Vivos Therapeutics Inc revenues increased 28% to $12.5M. Net loss increased from $5.8M to $12.9M. Revenues reflect Appliance sales to integrated providers segment increase of 40% to $4.5M, VIP segment increase of 11% to $6.4M. Higher net loss reflects General and administrative increase of 54% to $17.7M (expense), Sales and marketing increase from $1.5M to $4.2M (expense).

Industry: Medical Equipment

7921 Southpark Plaza,
Suite 210
80120

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.090% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

39,743.35 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading